In the absence of head-to-head trials, the findings help validate the applicability of phase 3 results to routine care. The study was published as a preprint and has not yet been peer reviewed.
The commonly used pain killer was strongly associated with a diminished response to immune checkpoint inhibitors in a study of 600 patients with cancer.
Colorado urologist Henry M. Rosevear, MD, offers his take on the scientific highlights of this year s annual meeting of the American Urological Association.
Clinicians are wondering whether measuring programmed death–ligand 1 (PD-L1) is essential before prescribing checkpoint inhibitors for gastroesophageal cancer.